Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 1Renal Insufficiency 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Kidney Neoplasms 1Kidney Diseases 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Kidney Transplantation 3Paclitaxel 2Carboplatin 2vinflunine 1veliparib 1trifluridine tipiracil drug combination 1trebananib 1ripretinib 1pembrolizumab 1belantamab mafodotin 1Zoledronic Acid 1Urination 1Taxes 1Stents 1Standard of Care 1Sitagliptin Phosphate 1Polymerase Chain Reaction 1Oxaliplatin 1Nephrotomy 1Nephrostomy, Percutaneous 1Ice 1Health Information Exchange 1Gemcitabine 1Duration of Therapy 1Cyclosporine 1Cyclophosphamide 1Blood Specimen Collection 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Renal Insufficiency × trebananib × Genitourinary × Clear all
NCT01331941 2017-11-06

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Amgen

Phase 1 Completed
35 enrolled
Genitourinary

Kidney Diseases, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡